Last reviewed · How we verify

Morphine, Parecoxib

Pfizer · FDA-approved active Small molecule

This is a combination of morphine (an opioid mu-receptor agonist) and parecoxib (a selective COX-2 inhibitor) that provides analgesia through both opioid and anti-inflammatory pathways.

This is a combination of morphine (an opioid mu-receptor agonist) and parecoxib (a selective COX-2 inhibitor) that provides analgesia through both opioid and anti-inflammatory pathways. Used for Acute postoperative pain, Moderate to severe pain requiring opioid analgesia.

At a glance

Generic nameMorphine, Parecoxib
SponsorPfizer
Drug classOpioid analgesic combined with selective COX-2 inhibitor
TargetMu-opioid receptor (morphine); COX-2 enzyme (parecoxib)
ModalitySmall molecule
Therapeutic areaPain Management
PhaseFDA-approved

Mechanism of action

Morphine binds to mu-opioid receptors in the central nervous system to reduce pain perception and emotional response to pain. Parecoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing prostaglandin synthesis and inflammation at the site of injury. The combination provides multimodal analgesia for enhanced pain relief with potentially lower opioid requirements.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: